Uncategorized
Treat-and-extend treatment benefits maintained at 3 years
SAN DIEGO — Mean visual acuity and anatomical improvements were sustained at 3 years using a treat-and-extend regimen for neovascular age-related macular degeneration, according to a speaker at the American Society of Retina Specialists annual meeting.Carl D. Regillo, MD, FACS, and colleagues have been following up patients receiving treat-and-extend therapy with bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) to determine long-term treatment outcomes.